Development of a locus-specific SBDS sequencing assay and clinical characterization of the first Ukrainian cohort with Shwachman-Diamond syndrome

Background Shwachman–Diamond syndrome (SDS) is a rare inherited disorder that is often challenging to diagnose because of its variable clinical presentation and overlap with other conditions. Data on the genetic spectrum of SDS in Ukraine are limited. Implementing molecular genetic testing may improve diagnostic accuracy and facilitate earlier identification of affected individuals. Methods Peripheral blood samples were collected from patients in Ukraine with suspected SDS. In most patients, the SBDS gene was analyzed using an in-house locus-specific PCR followed by Sanger sequencing, designed to minimize interference from the highly homologous SBDSP pseudogene. For the remaining patients, SBDS results obtained from external diagnostic laboratories using Sanger sequencing or Whole exome sequencing (WES) were included. Identified variants were interpreted according to ClinVar, and clinical data were obtained from medical records and families. Results Before implementation of in-house testing, genetic diagnosis of SDS was unavailable in Ukraine. Using the established SBDS sequencing workflow, we confirmed SDS in 8 children from 8 unrelated families and included 5 additional previously diagnosed patients. Among 13 patients from 12 unrelated families, the most prevalent genotype was c.[258 + 2T>C];[183_184delinsCT], identified in 10 patients (including 2 siblings). Other detected genotypes included c.[258 + 2T>C];[673_677del], c.[258 + 2T>C];[258 + 2T>C], and c.[258 + 2T>C];[183_184delinsCT, 258 + 2T>C]. Conclusions Our results show that genetic testing is essential for confirming SDS, guiding treatment and follow-up, and informing patients and families about the possible risk of myelodysplastic syndrome or acute myeloid leukemia. Early diagnosis is particularly important because SDS lacks population-based screening programs and may initially present with nonspecific clinical features.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-18
DOI
https://doi.org/10.3389/fimmu.2026.1974588
Primary Topic
Blood disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development of a locus-specific SBDS sequencing assay and clinical characterization of the first Ukrainian cohort with Shwachman-Diamond syndrome

Elena Boldyreva, Oksana R. Boyarchuk, Nataliya P. Matiytsiv, O.V. Tykholaz et al.
2 links
Frontiers in Immunology
Blood disorders and treatments
article

Development of a locus-specific SBDS sequencing assay and clinical characterization of the first Ukrainian cohort with Shwachman-Diamond syndrome

Elena Boldyreva, Oksana R. Boyarchuk, Nataliya P. Matiytsiv, O.V. Tykholaz, Halyna Makukh, Olena Kyselova, Anastasiia V. Bondarenko, Volodymyr S. Kravets, Mariya Dushar, Olga Bobkova
article en

Abstract

Background Shwachman–Diamond syndrome (SDS) is a rare inherited disorder that is often challenging to diagnose because of its variable clinical presentation and overlap with other conditions. Data on the genetic spectrum of SDS in Ukraine are limited. Implementing molecular genetic testing may improve diagnostic accuracy and facilitate earlier identification of affected individuals. Methods Peripheral blood samples were collected from patients in Ukraine with suspected SDS. In most patients, the SBDS gene was analyzed using an in-house locus-specific PCR followed by Sanger sequencing, designed to minimize interference from the highly homologous SBDSP pseudogene. For the remaining patients, SBDS results obtained from external diagnostic laboratories using Sanger sequencing or Whole exome sequencing (WES) were included. Identified variants were interpreted according to ClinVar, and clinical data were obtained from medical records and families. Results Before implementation of in-house testing, genetic diagnosis of SDS was unavailable in Ukraine. Using the established SBDS sequencing workflow, we confirmed SDS in 8 children from 8 unrelated families and included 5 additional previously diagnosed patients. Among 13 patients from 12 unrelated families, the most prevalent genotype was c.[258 + 2T>C];[183_184delinsCT], identified in 10 patients (including 2 siblings). Other detected genotypes included c.[258 + 2T>C];[673_677del], c.[258 + 2T>C];[258 + 2T>C], and c.[258 + 2T>C];[183_184delinsCT, 258 + 2T>C]. Conclusions Our results show that genetic testing is essential for confirming SDS, guiding treatment and follow-up, and informing patients and families about the possible risk of myelodysplastic syndrome or acute myeloid leukemia. Early diagnosis is particularly important because SDS lacks population-based screening programs and may initially present with nonspecific clinical features.

Frontiers in ImmunologyVol. 17
Lviv University (UA), Zaporizhzhia State Medical and Pharmaceutical University (UA), Kharkiv State Academy of Culture (UA), National Pirogov Memorial Medical University, Vinnytsya (UA), Kharkiv Regional Clinical Psychiatric Hospital No 3 (UA), National Academy of Medical Sciences of Ukraine (UA), I.Horbachevsky Ternopil National Medical University (UA), International European University (UA)
Good health and well-being
Blood disorders and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon